Black Diamond Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2018 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Black Diamond Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2018 to Q3 2024.
  • Black Diamond Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$15.6M, a 32.4% increase year-over-year.
  • Black Diamond Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$73.1M, a 13.1% increase year-over-year.
  • Black Diamond Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$82.4M, a 9.57% increase from 2022.
  • Black Diamond Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$91.2M, a 27.4% increase from 2021.
  • Black Diamond Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$126M, a 86.7% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$73.1M -$15.6M +$7.45M +32.4% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-05
Q2 2024 -$80.5M -$19.9M -$757K -3.95% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-05
Q1 2024 -$79.8M -$18.2M +$2.65M +12.7% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-05
Q4 2023 -$82.4M -$19.4M +$1.67M +7.92% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-12
Q3 2023 -$84.1M -$23M -$1.35M -6.25% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-05
Q2 2023 -$82.8M -$19.2M +$3.78M +16.5% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-05
Q1 2023 -$86.5M -$20.9M +$4.63M +18.2% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-05
Q4 2022 -$91.2M -$21.1M +$4.79M +18.5% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-12
Q3 2022 -$96M -$21.7M +$13.4M +38.3% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-06
Q2 2022 -$109M -$22.9M +$11.4M +33.2% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-06
Q1 2022 -$121M -$25.5M +$4.79M +15.8% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-06
Q4 2021 -$126M -$25.9M -$3.24M -14.3% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-09
Q3 2021 -$122M -$35.1M -$17.2M -95.8% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 -$105M -$34.4M -$19.8M -136% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-08
Q1 2021 -$85.4M -$30.3M -$18.2M -149% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-08
Q4 2020 -$67.3M -$22.6M -$12.8M -129% Oct 1, 2020 Dec 31, 2020 10-K 2021-03-25
Q3 2020 -$54.5M -$17.9M -$8.64M -93.3% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-08
Q2 2020 -$45.9M -$14.6M -$2.28M -18.6% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-08
Q1 2020 -$43.6M -$12.1M -$8.32M -217% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-08
Q4 2019 -$35.3M -$9.88M -$6.81M -222% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-25
Q3 2019 -$28.4M -$9.27M -$6.91M -293% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-25
Q2 2019 -$21.5M -$12.3M -$10.4M -542% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-25
Q1 2019 -$11.2M -$3.83M -$2.24M -140% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-25
Q4 2018 -$8.93M -$3.07M Oct 1, 2018 Dec 31, 2018 10-K 2020-03-24
Q3 2018 -$2.36M Jul 1, 2018 Sep 30, 2018 10-K 2020-03-24
Q2 2018 -$1.91M Apr 1, 2018 Jun 30, 2018 10-K 2020-03-24
Q1 2018 -$1.59M Jan 1, 2018 Mar 31, 2018 10-K 2020-03-24
* An asterisk sign (*) next to the value indicates that the value is likely invalid.